DuPont, embroiled in a proxy war with activist investor Trian Fund Management LP for board seats, said it would hold its annual shareholder meeting on May 13,Reuters reported. Trian has proposed adding Chief Executive Nelson Peltz and another nominee to DuPont’s board as well as two other nominees to the board of a unit DuPont plans to spin off. DuPont has rejected Trian’s repeated demands to add Peltz to its board, but has said it is prepared to accept one of the fund’s nominees, John Myers, in an attempt to end the proxy war. “One of the key reasons Peltz wants to get on (the board) is that he doesn’t think anyone would push for a breakup (of DuPont) like he would,” a person familiar with the matter told Reuters on Monday. DuPont had said it would spin off its performance chemicals business, but Peltz wants the company to separate its nutrition and health, agriculture and industrial biosciences divisions from its volatile but cash flow-strong materials businesses.